TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02920775

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review

Intervention type: OTHER
Intervention: Non-interventional study - retrospective database review
Study: NCT06564519

Intervention type: DEVICE
Group type: OTHER
Intervention: Posture Biofeedback Device
Description: Participants will wear a commercially available posture training device for a two-week tracking period and a two-week training period while performing laparoscopic procedures.
Study: NCT05396105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deucrictibant selected dose
Description: deucrictibant soft capsule for oral use
Study: NCT06263088

Intervention type: OTHER
Group type: OTHER
Intervention: EQUITY GI
Description: 1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis.
Study: NCT05726682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445419
Description: Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
Study: NCT05978505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 MG Oral Tablet
Description: 7 nightly doses (4mg) to commence after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 nightly doses to commence after surgery.
Study: NCT05425251

Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP and UCH-L1
Description: 2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.

Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP and UCH-L1
Description: 2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
Study: NCT04836117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SomaSignal Test Results
Description: SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
Study: NCT04789902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SurgeCon
Description: The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SurgeCon
Description: The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SurgeCon
Description: The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SurgeCon
Description: The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
Study: NCT05684913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zn granulate stent after FGG surgery
Description: Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostatic agent suturing
Description: Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
Study: NCT06248840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
Study: NCT05347238

Intervention type: DRUG
Intervention: Dopamine
Description: Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.

Intervention type: DRUG
Intervention: Norepinephrine
Description: Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
Study: NCT06097689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lab Demo 1.0
Description: Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid).
Study: NCT05265923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CM310
Description: IL-4Rα monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04943263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracheal Temperature
Description: Temperature measured from the endotracheal tube compared with the esophageal temperature
Study: NCT06366347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK inhibitor, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitor, tablet taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
Study: NCT05905497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
Study: NCT05760976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Advanced intravenous injection of cisatracurium before the succinylcholine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Advanced intravenous injection of cisatracurium before the succinylcholine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Advanced intravenous injection of cisatracurium before the succinylcholine injection
Study: NCT05036928

Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte distribution width (MDW）
Description: All enrolled patients will receive test with MDW.
Study: NCT05133271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical hemodynamic and echocardiographic evaluation
Description: Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~1. T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~2. T2: clinico-ultrasound evaluation after performing the PLR.~   Then, clinical hemodynamic evaluation during two periods T3 and T4:~3. T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~4. T4: period after performing spinal anesthesia until clamping of the umbilical cord.
Study: NCT05641285

Intervention type: DEVICE
Intervention: The OtoSight Middle Ear Scope
Description: The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
Study: NCT06052423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
Study: NCT05573204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic Acid Oral Tablet
Description: Obeticholic acid used as 10 mg tablet once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit E
Description: Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
Study: NCT05324930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piscean collagen dressing
Description: Piscean collagen dressing

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline infused dressing
Description: Saline infused dressing
Study: NCT06612346

Intervention type: DEVICE
Intervention: Minimally Invasive Micro Trabeculostomy
Description: The MINT system is a surgical device designed to create a trabeculostomy within the eye.
Study: NCT06650163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Magnetic Resonance Imaging
Description: Undergo advanced MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Surgery
Description: Undergo brain surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immuno-Positron Emission Tomography Scan
Description: Undergo immuno-PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Biopsy
Description: Undergo stereotactic image-guided biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Crefmirlimab Berdoxam
Description: Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
Study: NCT06623214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulyft
Description: Micro Radiofrequency Skin Treatment Device(nebulyft)
Study: NCT06625983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRC decision tool
Description: CRC decision tool included in the primary care bundle questionnaire
Study: NCT06765005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10
Description: Subcutaneous injection, once every 4 weeks
Study: NCT06769165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Description: In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.
Study: NCT06769204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA SPRAY
Description: 2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
Study: NCT06769113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 1
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 2
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 3
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06768151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted CEA CAR-T
Description: Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted CEA CAR-T
Description: Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
Study: NCT06769698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC fianlimab+cemiplimab
Description: Fixed-Dose Combination (FDC) Administered per the protocol
Study: NCT05261724

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
Study: NCT05277636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine
Description: A dose of 125 mg racemic MDMA will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-3,4-methylenedioxymethamphetamine
Description: A dose of 125 mg enantiomeric S-MDMA will be administered.
Study: NCT06769698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered per the protocol
Study: NCT05277636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-3,4-methylenedioxymethamphetamine (125 mg)
Description: A dose of 125 mg enantiomeric R-MDMA will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-3,4-methylenedioxymethamphetamine (250 mg)
Description: A dose of 250 mg enantiomeric R-MDMA will be administered.
Study: NCT06765447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostasis with 3% NaOCl in direct pulp capping
Description: after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostasis with 3% NaOCl in direct pulp capping
Description: after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostasis with diode laser in direct pulp capping
Description: Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostasis with diode laser in direct pulp capping
Description: Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
Study: NCT06767241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive auricular vagus nerve stimulation
Description: Non-invasive transcranial direct current auricular vagus nerve stimulation (tDC-aVNS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care treatment for moderate to severe COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care treatment for moderate to severe COVID-19